Novel Purification of Advanced Biopharmaceutical Antibodies, Antibody Derivatives and Recombinant Proteins

先进生物制药抗体、抗体衍生物和重组蛋白的新型纯化

• 批准号: 10027865
• 金额: $ 16.52万
• 依托单位: PURIUS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10027865
• 关键词: Novel; Purification; Advanced; Biopharmaceutical; Antibodies

Purius is a startup business developing a novel system for the purification of biopharmaceutical drugs that we call "resin-free purification". In the increasingly competitive field of biologics manufacture, the complex purification process is often the most expensive contributor to cost of goods. We aim to eliminate that complexity by eliminating all the traditional processing steps, condensing them into one simplified, sustainable and radically cheaper operation. Our innovative technology has the potential to transform current biomanufacturing operations.This project looks to expand on our previous work on antibody purification, expanding the potential targets for our purification technology whilst rapidly increasing our experimental capabilities.Our team comprises of a group of experts in the field with years of industrial and academic experience with a track record of innovation in the field, and we believe we have developed a business plan that can rapidly move this technology to market at the lowest risk and in the shortest time possible. The grant funding can help us reach that goal, to help drug manufacturers, and ultimately, help patients.

Purius 是一家初创企业，开发一种用于纯化生物制药药物的新型系统，我们称之为“无树脂纯化”。在竞争日益激烈的生物制品制造领域，复杂的纯化过程往往是造成商品成本最昂贵的因素。我们的目标是通过消除所有传统的加工步骤，将其浓缩为一个简化的、可持续的且极其便宜的操作来消除这种复杂性。我们的创新技术有潜力改变当前的生物制造业务。该项目旨在扩展我们之前在抗体纯化方面的工作，扩大我们纯化技术的潜在目标，同时快速提高我们的实验能力。我们的团队由一群拥有多年工业和学术经验的该领域专家组成，在该领域拥有良好的创新记录，我们相信我们已经制定了一项商业计划，可以以最低的风险快速将该技术推向市场，并且 在最短的时间内。赠款资金可以帮助我们实现这一目标，帮助药品制造商，并最终帮助患者。